Effect of changing therapy from agalsidase beta to agalsidase alfa in patients with Fabry disease

被引：0
|
作者：
West, M [1 ]
Lemoine, K [1 ]
机构：
[1] Dalhousie Univ, Dept Med, Halifax, NS, Canada
来源：
ACTA PAEDIATRICA | 2006年 / 95卷
关键词：
D O I：
暂无
中图分类号：
R72 [儿科学];
学科分类号：
100202 ;
摘要：
引用
收藏
页码：136 / 136
页数：1
相关论文
共 50 条
  • [1] AGALSIDASE ALFA AND AGALSIDASE BETA FOR TREATMENT OF FABRY DISEASE
    Costa, M. G.
    Santos, M.
    Senna, K.
    VALUE IN HEALTH, 2018, 21 : S439 - S440
  • [2] Enzyme replacement therapy in Fabry disease: Comparison of agalsidase alfa and agalsidase beta
    Mehta, Atul
    Beck, Michael
    Kampmann, Christoph
    Frustaci, Andrea
    Germain, Dominique P.
    Pastores, Gregory M.
    Sunder-Plassmann, Gere
    MOLECULAR GENETICS AND METABOLISM, 2008, 95 (1-2) : 114 - 115
  • [3] Clinical observations on enzyme replacement therapy in patients with Fabry disease and the switch from agalsidase beta to agalsidase alfa
    Abcde, Hsiang-Yu Lin
    Huang, Yu-Hsiu
    Liao, Hsuan-Chieh
    Liu, Hao-Chuan
    Hsu, Ting-Rong
    Shen, Chia-I
    Li, Shao-Tzu
    Li, Cheng-Fang
    Lee, Li-Hong
    Lee, Pi-Chang
    Huang, Chun-Kai
    Chiang, Chuan-Chi
    Lin, Shuan-Pei
    Niu, Dau-Ming
    JOURNAL OF THE CHINESE MEDICAL ASSOCIATION, 2014, 77 (04) : 190 - 197
  • [4] SWITCH FROM AGALSIDASE BETA TO AGALSIDASE ALFA IN THE ENZYME REPLACEMENT THERAPY OF PATIENTS WITH FABRY DISEASE IN LATIN AMERICA
    Ripeau, Diego
    Amartino, Hernan
    Cedrolla, Martin
    Urtiaga, Luis
    Urdaneta, Bella
    Cano, Marilis
    Valdez, Rita
    Antongiovanni, Norberto
    Masllorens, Francisca
    MEDICINA-BUENOS AIRES, 2017, 77 (03) : 173 - 179
  • [5] SAFETY AND TOLERABILITY OF AGALSIDASE ALFA IN PATIENTS WITH FABRY DISEASE FORMERLY TREATED WITH AGALSIDASE BETA
    Fernhoff, P.
    Goker-Alpan, O.
    Holida, M.
    Nedd, K.
    Barshop, B. A.
    Mardach, R.
    Ibrahim, J.
    Lien, Y. H.
    Rever, B.
    Hillman, R.
    Weinreb, N.
    Boyd, E.
    Desai, A.
    Forte, R.
    Crombez, E.
    Martin, R.
    Amato, D.
    JOURNAL OF INHERITED METABOLIC DISEASE, 2011, 34 : S227 - S227
  • [6] EFFECT AND TOLERABILITY OF AGALSIDASE ALFA IN PATIENTS WITH FABRY DISEASE
    Goker-Alpan, O.
    Nedd, K.
    Shankar, S.
    Lien, Y. H.
    Barshop, B. A.
    Holida, M.
    Hillman, R.
    Ibrahim, J.
    Mardach, R.
    Weinreb, N.
    Rever, B.
    Forte, R.
    Desai, A.
    Wijatyk, A.
    Chang, P.
    Martin, R.
    JOURNAL OF INHERITED METABOLIC DISEASE, 2012, 35 : S148 - S148
  • [7] Antibody measurement on switching from agalsidase alfa to agalsidase beta in the treatment of Fabry disease
    Peters, C.
    Burling, K.
    Deegan, P. B.
    ACTA PAEDIATRICA, 2008, 97 : 111 - 112
  • [8] COST ANALYSIS FOR THE TREATMENT OF FABRY DISEASE WITH AGALSIDASE ALFA AND AGALSIDASE BETA IN COLOMBIA
    Londono, S.
    Pareja, M.
    Becerra, J.
    VALUE IN HEALTH, 2020, 23 : S693 - S693
  • [9] A COST ANALYSIS ON COMPLICATIONS OF FABRY DISEASE PATIENTS TREATED WITH AGALSIDASE ALFA AND AGALSIDASE BETA IN COLOMBIA
    Londono, S.
    Ossa, M. E.
    Becerra, J.
    Solano, D. A.
    VALUE IN HEALTH, 2023, 26 (06) : S91 - S91
  • [10] Clinical observation of patients with Fabry disease after switching from agalsidase beta (Fabrazyme) to agalsidase alfa (Replagal)
    Tsuboi, Kazuya
    Yamamoto, Hiroshi
    GENETICS IN MEDICINE, 2012, 14 (09) : 779 - 786
12345